Structure Therapeutics Inc. (NASDAQ:GPCR) shares are up during Monday’s premarket session following the release of positive topline data from the Phase 2 ACCESS II trial.

The stock’s rise comes as the company reported significant weight loss results from its investigational oral drug, aleniglipron, which is designed for treating obesity, while broader markets experienced mixed movements.

Structure Therapeutics Phase 2 Trial Shows Significant Weight Loss

Aleniglipron achieved a placebo-adjusted mean weight loss of 16.3% (39 lbs) at the 180 mg dose and 16.0% (37 lbs) at the 240 mg dose after 44 weeks, with no evidence of a weight loss plateau.

The interim data from the ongoing ACCESS Open Label Extension study showed continued weight loss of up to 16.2% (40.5 lbs) with the 120 mg dose at 56 weeks, demonstrating the drug’s efficacy and a favorable safety profile.

Structure Therapeutics also noted that the study had low discontinuation rates due to adverse events.

Phase 3 Plans And Regulatory Discussions

The company plans to hold an FDA end-of-Phase 2 meeting in the second quarter of 2026, with Phase 3 initiation on track for the second half of 2026.

Currently, the trial is designed with a starting titration dose of 2.5 mg with the intent to evaluate multiple doses up to 240 mg.

Structure Therapeutics CEO Highlights Aleniglipron Competitiveness

When asked what could make aleniglipron competitive, CEO Raymond Stevens pointed to four factors.

First, he highlighted efficacy, noting that a higher dose led to weight loss of up to 15.3% at 36 weeks.

Stevens said Structure has not observed drug-related liver injuries across studies.

Manufacturing cost also plays a role. As a small-molecule pill, aleniglipron can be produced at scale, positioning the company to supply the U.S. market efficiently.

Stevens emphasized the drug’s ability to be combined with other therapies.

Structure has shown that pairing its oral GLP-1 with an amylin-targeting drug produced synergistic effects.

Structure Therapeutics Technical Indicators Signal Mixed Momentum

The stock is currently trading 6.5% below its 20-day simple moving average (SMA) but is 1.3% above its 100-day SMA, indicating some short-term weakness while maintaining longer-term strength.

Over the past 12 months, shares have increased by 146.67%, and they are currently positioned closer to their 52-week highs than lows.

The RSI is at 25.42, which is considered oversold territory, suggesting potential for a rebound. Meanwhile, MACD is at -5.0890, below its signal line at -4.3399, indicating bearish pressure on the stock.

The combination of oversold RSI and bearish MACD suggests mixed momentum, indicating that while the stock is oversold, the bearish MACD reflects ongoing selling pressure.

  • Key Resistance: $73.00
  • Key Support: $59.00

Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $101.20. Recent analyst moves include:

  • HC Wainwright & Co.: Buy (Raises Target to $114.00) (Mar. 2)
  • Citizens: Market Outperform (Lowers Target to $113.00) (Feb. 27)
  • JP Morgan: Overweight (Raises Target to $105.00) (Jan. 22)

Structure Therapeutics Benzinga Edge Rankings

Below is the Benzinga Edge scorecard for Structure Therapeutics, highlighting its strengths and weaknesses compared to the broader market:

  • Momentum: Strong (Score: 97.89) — Stock is outperforming the broader market.

The Verdict: Structure Therapeutics’ Benzinga Edge signal reveals a strong momentum score, indicating that the stock is currently outperforming the broader market. This momentum, combined with positive trial results, positions the company favorably for future growth.

Top ETF Exposure

  • SPDR S&P Emerging Markets Small Cap ETF (NYSE:EWX): 0.18% Weight
  • State Street SPDR S&P Emerging Markets Small Cap ETF (NYSE:EWX): 0.35% Weight
  • ALPS Medical Breakthroughs ETF (NYSE:SBIO): 3.17% Weight

GPCR Price Action: Structure Therapeutics shares were up 7.94% at $58.02 during premarket trading on Monday, according to Benzinga Pro data.

Image via Shutterstock